New study aims to stop melanoma relapse after surgery
NCT ID NCT04741997
First seen Oct 31, 2025 · Last updated Jun 15, 2026 · Updated 34 times
Summary
This study looks at whether giving additional treatment after surgery can reduce the chance of melanoma returning in people with advanced stage III or IV melanoma that has a BRAF V600 mutation. About 50 participants will receive a combination of drugs (encorafenib and binimetinib) before surgery, then based on how much the tumor shrinks, they may get more treatment after surgery. The goal is to see if this approach lowers the relapse rate and improves how long people stay cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.